Literature DB >> 25900177

Serum prolidase levels in Graves' disease without ophthalmopathy and its association with oxidative status.

H Korkmaz1, S Tabur2, M Ozkaya2, E Oguz3, N Aksoy4, E Akarsu2.   

Abstract

OBJECTIVE: The aim of this study was to evaluate serum prolidase levels and its association with oxidative stress in autoimmune thyroid disease (AITD).
MATERIALS AND METHODS: 25 with Hashimoto thyroiditis (HT) and 25 patients Graves' disease (GD), and 27 healthy controls were enrolled in the study. The patients with signs of Graves' ophthalmopathy were excluded from the study. Serum samples were obtained in euthyroid period at the third month of treatment. Serum prolidase, total antioxidant status (TAS), total oxidative stress (TOS), and total free sulfhydryl (-SH) levels were measured.
RESULTS: Serum prolidase levels were significantly higher in the patients with GD compared to the HT and the healthy control group. Oxidative stress index (OSI) and TOS levels of the patients with both GD and HT were significantly higher compared to those of the control group (p < 0.001, for each), while -SH levels were significantly lower (p < 0.001, for each). There was no significant difference between the patients with HT and healthy control group in terms of prolidase levels (p = 0.580). Prolidase levels were positively correlated with TOS and OSI and negatively correlated with -SH (r = 0.565, p = 0.003; r = 0.604, p = 0.001; r = -0.532, p = 0.006).
CONCLUSION: Serum prolidase activity is increased in GD patients without signs of ophthalmopathy, and showed a positive correlation with oxidative stress parameters.

Entities:  

Keywords:  Graves’ disease; Hashimoto’s thyroiditis; Oxidative status; Prolidase

Mesh:

Substances:

Year:  2015        PMID: 25900177     DOI: 10.1007/s40618-015-0278-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

Review 2.  Matrix metalloproteinases.

Authors:  O Zitka; J Kukacka; S Krizkova; D Huska; V Adam; M Masarik; R Prusa; R Kizek
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

3.  Decreased total antioxidant capacity and increased oxidative stress in passive smoker infants and their mothers.

Authors:  Ali Aycicek; Ozcan Erel; Abdurrahim Kocyigit
Journal:  Pediatr Int       Date:  2005-12       Impact factor: 1.524

4.  Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis.

Authors:  Mehmet Horoz; Mehmet Aslan; Fusun F Bolukbas; Cengiz Bolukbas; Yasar Nazligul; Hakim Celik; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy.

Authors:  C Marcocci; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-11       Impact factor: 4.256

6.  A new automated colorimetric method for measuring total oxidant status.

Authors:  Ozcan Erel
Journal:  Clin Biochem       Date:  2005-10-07       Impact factor: 3.281

7.  Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy.

Authors:  Janusz Myśliwiec; Małgorzata Adamczyk; Przemysław Pawłowski; Agnieszka Nikołajuk; Maria Górska
Journal:  Endokrynol Pol       Date:  2007 Mar-Apr       Impact factor: 1.582

Review 8.  Diagnosis and classification of Graves' disease.

Authors:  Francesca Menconi; Claudio Marcocci; Michele Marinò
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

Review 9.  Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.

Authors:  Jean-Louis Beaudeux; Philippe Giral; Eric Bruckert; Marie-José Foglietti; M John Chapman
Journal:  Clin Chem Lab Med       Date:  2004-02       Impact factor: 3.694

10.  Graves' ophthalmopathy: a review of immunogenetics.

Authors:  Omid Khalilzadeh; Sina Noshad; Armin Rashidi; Aliakbar Amirzargar
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

View more
  2 in total

1.  Increased serum interleukin-37 (IL-37) levels correlate with oxidative stress parameters in Hashimoto's thyroiditis.

Authors:  R M Ruggeri; M Cristani; T M Vicchio; A Alibrandi; S Giovinazzo; A Saija; A Campennì; F Trimarchi; S Gangemi
Journal:  J Endocrinol Invest       Date:  2018-05-23       Impact factor: 4.256

2.  THE EFFECT OF ANTITHYROID DRUGS ON OSTEOPONTIN AND OXIDATIVE STRESS IN GRAVES' DISEASE.

Authors:  M Kocak; E Akarsu; H Korkmaz; S Taysi
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.